Flux Power Holdings Inc vs Medpace Holdings Inc — how do they compare? Flux Power Holdings Inc trades at $0.6 (market cap $11.23M), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 1504.9× Flux Power Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals.
| FLUX | MEDP | |
|---|---|---|
Market Cap | $11.23M | $16.90B |
Sector | Utilities | Technology |
52-Week High | $6.66 | $620.59 |
52-Week Low | $0.51 | $393.42 |
Enterprise Value | $17.39M | $16.52B |
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.5702, up 8.82% today, but technical indicators signal a bearish trend with moving averages and ADX showing sell signals. The company reported mixed quarterly results, missing EPS estimates in Q3 2025 and Q1 2026 while beating in Q4 2025. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 6 buy ratings. Recent developments include the upcoming Q4 2026 earnings call and the launch of SkyEMS 3.0 with AI-powered fleet insights.
FLUX presents a high-risk opportunity with strong analyst support but fundamental challenges. The bullish sentiment from Wall Street contrasts with persistent losses and negative ROE/ROA. Key catalysts include execution on new product launches and path to profitability, while risks involve sustained cash burn and competitive pressure in clean energy storage.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →